950176-70-2Relevant academic research and scientific papers
Hepatitis C Virus Inhibitors
-
Paragraph 0479-0480, (2015/02/25)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 112; 113, (2015/02/02)
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir
Belema, Makonen,Nguyen, Van N.,Bachand, Carol,Deon, Dan H.,Goodrich, Jason T.,James, Clint A.,Lavoie, Rico,Lopez, Omar D.,Martel, Alain,Romine, Jeffrey L.,Ruediger, Edward H.,Snyder, Lawrence B.,Laurent, Denis R. St.,Yang, Fukang,Zhu, Juliang,Wong, Henry S.,Langley, David R.,Adams, Stephen P.,Cantor, Glenn H.,Chimalakonda, Anjaneya,Fura, Aberra,Johnson, Benjamin M.,Knipe, Jay O.,Parker, Dawn D.,Santone, Kenneth S.,Fridell, Robert A.,Lemm, Julie A.,O'Boyle, Donald R.,Colonno, Richard J.,Gao, Min,Meanwell, Nicholas A.,Hamann, Lawrence G.
, p. 2013 - 2032 (2014/04/03)
The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit
HEPATITIS C VIRUS INHIBITORS
-
Page/Page column 157-158, (2009/10/09)
The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 96-97, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 97, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Hepatitis C Virus Inhibitors
-
Page/Page column 170, (2008/06/13)
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
